Лечение распространенного радиойод-рефрактерного фолликулярного рака щитовидной железы препаратом Ленватиниб: клинический случай
Автор: Бычков Ю.М., Большакова С.А.
Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr
Рубрика: Клинические наблюдения
Статья в выпуске: 4 т.17, 2017 года.
Бесплатный доступ
При дифференцированном раке щитовидной железы менее чем у 10% пациентов выявляются отдаленные метастазы. Приблизительно у 2/3 пациентов заболевание становится радиойод-рефрактерным, при этом уровень 10-тилетней выживаемости равен 10%, а средняя ожидаемая продолжительность жизни составляет 3-5 лет. Системная химиотерапия малоэффективна в данной ситуации, уровень ее токсичности достаточно высок. Мультикиназные ингибиторы, на сегодняшний день, являются наиболее изучаемыми препаратами при радиойод-рефрактерном дифференцированном раке щитовидной железы. Объективный ответ и достоверное увеличение выживаемости без прогрессирования отмечены при лечении ленватинибом и сорафенибом.
Дифференцированный рак щитовидной железы, радиойод-рефрактерный рак щитовидной железы, ингибиторы тирозинкиназ
Короткий адрес: https://sciup.org/14955561
IDR: 14955561
Treatment of advanced radioactive iodine refractory follicular thyroid cancer with multy kinase inhibitor Lenvatinib: a сase report
Only a few patients with differentiated thyroid cancer (less than 10% of patients with clinical disease) develop distant metastases. Two third of these patients become refractory to the treatment with radioactive iodine (RAI). After the discovery of advanced RAI-refractory disease, the 10-year survival rate is usually less than 10% and the mean life expectancy is 3-5 years. Systemic chemotherapy has a limited efficacy with a high toxicity rate. Multikinase inhibitors are being studied the most extensively in relation to advanced RAI-refractory disease. Two of multikinase inhibitors, lenvatinib and sorafenib have shown an objective response rate and have significantly improved the progression-free survival rates.
Список литературы Лечение распространенного радиойод-рефрактерного фолликулярного рака щитовидной железы препаратом Ленватиниб: клинический случай
- MiyauchiA., KudoT., MiyaA., et al. Prognostic impact of serum thyroglobulin doubling -time under thyrotropin suppression in patients with papillary Thyroid carcinoma who underwent total Thyroidectomy. Thyroid. 2011. V. 21. N. 7. P. 707-716.
- Yeung K.T., Cohen E.E. Lenvatinib in advanced, radioactive iodine -refractory, differentiated thyroid carcinoma. Clin Cancer Res. 2015. V. 21. N. 24. P. 5420-5426.
- Alberto A., Lopez J.E., Torres A., et al. Effectiveness of chemotherapy in advanced differentiated thyroid cancer: a systematic review. Endocr Relat Cancer. 2016. V. 23. N. 2. R. 71-84.
- Arighi E., Borrello M.G., Sarida H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev. 2005. V. 16. N. 4-5. P. 441-467.
- Haugen B.R., Alexander E.K., Bible K.C., et al. 2015 American Thyroid association Management Guidelines for Adult Patients with Thyroid Nodules and differentiated Thyroid cancer. The American Thyroid Association Guidlines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016. V. 26. N. 1. P. 1-133.
- Bhaijee F.L., Nikiforov Y.E. Molecular analysis of thyroid tumors. Endocr Pathol. 2011. V.22. N. 3. P. 126-133.
- Brose B.R., Nutting C.M., Jarzab B., et al.Sorafenib in locally advanced or metastatic, radioactive iodinereractory, differentiated thyroid cancer: a randomized, double-blind, phase 3 trial. Lancet. 2014. V. 384. N. 9940. P. 319-328.
- Brose M.S., Frenette C.T., Keefe S.M., et al. Management of sorafenib -related adverse events: a clinician’s perspective. Semin Oncol. 2014. V. 41. Suppl. S1-S16.
- Brose M.S., Smit J., Capdevila J., et al. Regional approaches to the management of patients with advanced, radioactive, iodine-refractory differentiated thyroid carcinoma. Expert Rev Anticancer Ther. 2012. V. 12. N. 9. P. 1137-1147.
- Capp C., Wajner S.M., Sigueira D.R., et al. Increased expression of vascular endothelial growth factor and its receptor, VEGFR-1 and VEGFR-2 in medullary Thyroid carcinoma. Thyroid. 2010. V. 20. N. 8. P. 863-871.
- De Besi P., Busnardo B., Toso S., et al. Combined chemotherapy with bleomycin, Adriamycin and platinum in advanced thyroid cancer. J Endocrinol Invest. 1991. V. 14. N. 6. P. 475-480.
- Durante C., Haddy N., Baudin E., et al. Long -term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006. V. 91. N. 8. P. 2892-2899.
- Haeat M.J., Howlader N., Reichman M.E., et al. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology and End Results (SEER) Program. Oncologist. 2007. V. 12. N. 1. P. 20-37.
- Koo B.S., Kim J.M., Seo S.T., et al. Upregulation of HGF and c-MET is associated with subclinical central lymph node metastases in papillary thyroid microcarcinoma. Ann Surg Oncol. 2014. V. 21. N. 7. P. 2310-2317.
- Orlandi E., Caraci P., Berruti A., et al. Chemotherapy with dacarbasine and 5-fluorouracil in advanced medullary thyroid cancer. Ann Oncol. 1994. V. 5. N. 8. P. 763-765.
- Pappotti M., Olivero M., Volante M., et al. Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid. Endocr Pathol. 2000. V. 11. N. 1. P. 19-30.
- Pitoia F., Jerkovich F. Selective use of sorafenib in the treatment of thyroid cancer. Drug Des Devel Ther. 2016. V. 10. P. 1119-1131.
- Schlumberger M. Prise en charge des cancers refractaores de la thyroid. Annales d'Endocrinologie. 2011. V. 72. P. 149-157.
- Schlumberger M., Sherman S.I. Approach to the patients with advanced differentiated thyroid cancer. Eur J Endocrinol. 2012. V. 166. N. 1. P. 5-11.
- Schlumberger M., Tahara M., Wirth L.J., et al. Lenvatinib versus placebo in radioiodine -refractory thyroid cancer. N Engl J Med. 2015. V. 372. N. 7. P. 621-630.
- Schmidt A., Iglesias L., Klain M., et al. Radioactive iodine -refractory differentiated thyroid cancer: an uncommon but challenging situation. Arch Endocrinol Metab. 2017. V. 61. N. 1. P. 81-89.
- Xing M. Gene methylation in thyroid tumorigenesis. Endocrinology. 2007. V. 148. N. 3. P. 948-953.
- Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013. V. 13. N. 3. P. 184-199.
- Yaish P., Gazit A., Gilon C., et al. Blocking of EGFR -dependent cell proliferation by EGF receptor kinase inhibitors. Science. 1988. V. 242. N. 4880. P. 933-935.
